Traders Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)

Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Friday. $505.64 million flowed into the stock on the tick-up and $730.37 million flowed out of the stock on the tick-down, for a money net flow of $224.73 million out of the stock. Of all companies tracked, Johnson & Johnson had the 0th highest net out-flow for the day. Johnson & Johnson traded up $0.27 for the day and closed at $134.45

Several brokerages have recently commented on JNJ. BMO Capital Markets restated a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a report on Friday, September 1st. UBS AG restated a “buy” rating and issued a $148.00 price objective on shares of Johnson & Johnson in a report on Thursday, August 31st. Cowen and Company set a $147.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Thursday, August 24th. Jefferies Group LLC set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Tuesday, August 15th. Finally, J P Morgan Chase & Co increased their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a report on Wednesday, August 16th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $134.60.

The stock has a market cap of $360.86 billion, a price-to-earnings ratio of 22.75 and a beta of 0.79. The firm’s 50 day moving average price is $132.62 and its 200 day moving average price is $129.18.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the previous year, the company posted $1.74 earnings per share. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.50%. Johnson & Johnson’s payout ratio is currently 56.76%.

In related news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after acquiring an additional 3,023,110 shares in the last quarter. BlackRock Inc. raised its holdings in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after acquiring an additional 4,332,612 shares in the last quarter. State Street Corp raised its holdings in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares in the last quarter. FMR LLC raised its holdings in Johnson & Johnson by 5.9% in the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after acquiring an additional 1,509,745 shares in the last quarter. Finally, Capital World Investors raised its holdings in Johnson & Johnson by 4.1% in the second quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after acquiring an additional 1,050,000 shares in the last quarter. 66.00% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Traders Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://ledgergazette.com/2017/09/17/traders-sell-shares-of-johnson-johnson-jnj-on-strength-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply